CoChat

TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Clinical Trial Protocol ANZUP 1603)

Open access
Hofman, Michael S., Emmett, Louise, Violet, John, Y. Zhang, Alison, Lawrence, Nicola J., Stockler, Martin, Francis, Roslyn J., Iravani, Amir, Williams, Scott, Azad, Arun, Martin, Andrew, McJannett, Margaret, ANZUP TheraP team, Davis, Ian D. · 2019 · BJU International
Cited by 165

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Objective: To assess the activity and safety of cabazitaxel chemotherapy vs that of treatment with 177 Lu‐ PSMA ‐617, a novel radiolabelled small molecule that binds with high affinity to prostate‐specific membrane antigen ( PSMA ), in men with metastatic castration‐resistant prostate cancer ( mCRPC ) who have received prior docetaxel treatment. Patients and methods: The TheraP trial ( ANZUP 1603) is an open‐label, randomized, stratified, two‐arm multicentre phase 2 trial comparing the activity and safety of cabazitaxel chemotherapy vs 177 Lu‐ PSMA ‐617 therapy in the treatment of men with mCRPC . Key eligibility criteria include prior docetaxel chemotherapy, rising prostate‐specific antigen ( PSA ) level, sufficient PSMA avidity, as defined by centrally reviewed 68 Ga‐ PSMA ‐11 and fluorodeoxyglucose ( FDG )‐positron emission tomography ( PET )/computed tomography ( CT ) with no discordant FDG ‐avid PSMA ‐negative sites of disease. Patients in the control group receive standard treatment with cabazitaxel (20 mg/m 2 ) i.v. every 3 weeks with prednisolone 10 mg daily orally, for a maximum of 10 cycles. Patients in the experimental group receive 177 Lu‐ PSMA ‐617 (8.5 GB q decreasing by 0.5 GB q per cycle) i.v. every 6 weeks, for up to a maximum of six cycles. In the event of an exceptional response as defined on centrally reviewed post‐therapy single‐photon emission CT imaging, treatment will be suspended but can recommence on progression. The trial aims to include 200 patients who will be centrally randomized to one of the two treatment groups, in a 1:1 ratio. The primary endpoint is PSA response. Secondary endpoints are overall survival, progression‐free survival ( PFS ), radiographic PFS , PSA PFS , objective tumour response, pain response, pain PFS , health‐related quality of life, and frequency and severity of adverse events. The treatment and outcomes of patients excluded on the basis of low PSMA avidity or discordant FDG ‐avid disease on screening 68 Ga‐ PSMA ‐11 and Fluorine‐18 ( 18 F)‐ FDG ‐ PET / CT scan will also be assessed. Enrolment in the study commenced on 29 January 2018. Results and Conclusions: 177 Lu‐ PSMA ‐617 offers a potential additional life‐prolonging treatment option for men with mCRPC . The results of this trial will determine, for the first time in a randomized design, the activity and safety of 177 Lu‐ PSMA ‐617, as compared with cabazitaxel chemotherapy in men with progressive mCRPC .

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/bju.14876

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 165

Metadata

Authors
Hofman, M. S., Emmett, L., Violet, J., Y. Zhang, A., Lawrence, N. J., Stockler, M., Francis, R. J., Iravani, A., Williams, S., Azad, A., Martin, A., McJannett, M., ANZUP TheraP team, & Davis, I. D.
Venue
BJU International
Publisher
Wiley
Published
2019-10-22
Volume
124
Issue
S1
Pages
5-13
ISSN
  • 1464-4096 (ISSN-L)
  • 1464-410X
OpenAlex
W2981468397
Cited by
165
References
10
FWCI
13.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.